glp gip glucagon & cagrilintide The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Receptor GLP-3 Cagrilintide Research Peptide |

There are three method categories: M1 (manipulation of blood and blood components), M2 (chemical and physical manipulation) and M3 (gene and cell doping)

Tirzepatide is an FDA- and EMA-approved dual GIP/GLP-1 receptor agonist with multiple completed Phase 3 trials behind it

Unlike standard protocols that may show effects within days, micro-dosing often requires weeks before meaningful changes become apparent

Research to date highlights MOTS-cs ability to promote metabolic homeostasis (improving insulin sensitivity, encouraging fat utilization, and preventing diet-induced metabolic disorders) as well as its potential to mitigate aspects of aging (preserving muscle function, bone density, vascular health, and more)